Tumor-derived IFN favors the expression of PDL1 in tumor cells via IFNAR1/STAT1 and PD1 in immune cells, resulting in immune suppression in head and neck malignancies (HNSCCs) [122]. Here, STAT1 is linked to neoplasm.